# OnCo record paper-nct06396065-lancet-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct06396065-lancet-oncol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct06396065-lancet-oncol-2026" ;
  schema:name "Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial"@en ;
  schema:description "Published report from the trial registered as NCT06396065, in The Lancet Oncology (2026), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct06396065-lancet-oncol-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(26)00282-2>, <https://pubmed.ncbi.nlm.nih.gov/42636833/>, <https://europepmc.org/article/MED/42636833>, <https://clinicaltrials.gov/study/NCT06396065> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(26)00282-2> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Le X, Passaro A, Zhao Y, et al." ;
  onco:trials <https://onco.cc/trials/nct06396065/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .